ESMO Congress 2024: Press & Media

Congress highlights

Take a look at our event announcement and find out what to expect during 5 intense days of new data, lectures and discussions.

News Releases

• Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe
• From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing, the ESMO Congress 2024 Takes a Holistic View of Oncology
• Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group of Women with Early-Stage Disease
• Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers

Press accreditation

ESMO welcomes Press Representatives interested in obtaining information and reporting on cancer issues. Accreditation is free to Press Representatives working for ESMO-Recognised Press Outlets on presentation of a letter of assignment and a valid press card (if applicable). Press Representatives are required to observe and abide by the ESMO Policy on Press Activities which applies to all ESMO events. 

To apply for press accreditation, please fill out the form available here:

Complete the press accreditation form

ESMO Opening Press Conference

The ESMO Congress 2024 Opening Press Conference will be held onsite in the ESMO Press Conference Room located in Hall CC3 (Level 1) on Friday, 13 September, 10:30-11:15 CEST.  Access will be granted to accredited Press Representatives attending both in-person or remotely. 

Relevant congress highlights, the relationship between a fast-changing technological and therapeutic environment and a workforce fit-for purpose, will be the topics explored at the ESMO 2024 Opening Press Conference.

Panellists 

• Andrés Cervantes, INCLIVA – Biomedical Research Institute, Spain – ESMO President
• Rebecca Dent, National Cancer Center Singapore, Republic of Singapore – ESMO 2024 Scientific Chair

Moderator 

• Angela Lamarca, Fundacion Jimenez Diaz University Hospital, Spain - ESMO 2024 Press Officer

Data and information included in abstracts discussed during the ESMO Opening Press Conference is under embargo until the relevant embargo release date cited in the schedule below.

Data and information beyond abstracts discussed during the ESMO Opening Press Conference, e.g., full data sets, may only be made public at the start of the official programme session during which the study is presented.

ESMO Press Conferences

Press Conferences will be held during the Congress days (12:30-13:15 CEST) to engage press representatives in discussions concerning promising topics in oncology research, featuring some of the studies presented.

All ESMO Press Conferences are held under embargo. 

Data and information included in LBAs discussed during the ESMO Press Conferences is under embargo until 00:05 CEST on their day of presentation.

Data and information beyond LBAs discussed during the ESMO Press Conferences, e.g., full data sets, may only be made public at the start of the official programme session during which the study is presented.

Past, present and future of gynaecological cancers

Endometrial cancer has approved immunotherapy (IO) in combination with chemotherapy for advanced and recurrent cases, though its effectiveness varies and is generally less pronounced. In contrast, cervical cancer shows better responses to both radiation therapy (RT) and IO. Regarding the future of gynaecological oncology, where are we heading with the latest immunotherapy research and its potential in treatment strategies?

Abstracts: 709O, LBA28, 721MO

Immunotherapy: Current Insights and Future Directions

Immunotherapy has shown promising results improving survival for patients across many diseases. Research presented at the ESMO Congress 2024 reports long-term survivorship benefits of immunotherapy in melanoma (10 years), however, some studies have conveyed specific negative outcomes. What are the long-term effects on triple negative breast cancer and bladder cancer, and what lies ahead for investigational immunotherapy?

Abstracts: LBA43, LBA44, LBA45, LBA4, LBA5

 New avenues in cancer research and care

Innovative approaches, emerging and forward-looking discussions on topics ranging from the integration of AI applied to molecular diagnostics and treatment, through the application of systemic therapies to improve the quality of life of the patients, from the need to investigate treatment resistance to pioneering solutions for poorly covered disease settings. 

Abstracts: LBA7, 1942O, 509O, LBA8, 604O

Publication schedule for accepted abstracts

• All regular abstracts accepted for presentation at the ESMO Congress 2024 as Proffered Paper (suffix O), Mini Oral (suffix MO), Poster (suffix P or TiP), EONS Proffered Paper, EONS Rapid Fire and EONS Posters (prefix CN), will be published online via the ESMO website at 00:05 CEST on Monday, 9 September 2024.
• All Late-breaking abstracts accepted for presentation at the ESMO Congress 2024 as Proffered Paper or Mini Oral (prefix LBA) will be published online via the ESMO website at 00:05 CEST on the day of presentation. 
• Both regular and Late-breaking abstracts featured in the ESMO Communication Activities will respect their original embargo (no dedicated embargo). Details on ESMO Communication Activities are indicated in the previous paragraphs.

Embargo policy  

Data and information included in accepted abstracts is under embargo until the relevant embargo release date cited in the schedule above. 

Data and information beyond what is included in the accepted abstracts, e.g., full data sets, may only be made public at the start of the official programme session during which the study is presented.

Third Party Media Activities and Registration

Media Activities initiated by Third Parties during or in connection with the event are subject to the ESMO Policy on Media Activities Organised by Third Parties which aims to guarantee proper and correct distribution of oncology and cancer-related information to Press Representatives in connection with the conference. Such Media Activities include (but are not limited to): 

• TP Media events such as press conferences, media briefings and educational sessions involving Press Representatives. 
• PR activities, such as press releases, news, articles, interviews, etc. 

TP Media events concomitant with/or during breaks of the scientific programme of the ESMO event are subject to ESMO’s approval. 
According to the ESMO Policy on Press Activities, press badges may only be assigned to Press Representatives working for ESMO-Recognised Press Outlets. Should communication agencies or companies representatives require a badge for the purpose of preparing and/or developing Third Party Media events, please send an email to ESMO Registration (registration@esmo.org – Cc media@esmo.org) to purchase a dedicated badge and/or send a request to media@esmo.org to book a meeting room.

Filming Activities

All Filming Activities performed during or in connection with the event, are subject to the ESMO Policy on Filming Activities. 

Press Representatives can announce their Filming Activities while applying for a press accreditation (see above).

Third Parties can request specific guidance, purchase a dedicated badge and/or book a filming room by sending a request to filming@esmo.org.

Blackout times  

During Blackout times any media event initiated by Third Parties is not allowed. 

PLEASE NOTE:   1:1 interviews and press releases are not affected by Blackout times but must respect Embargo and official programme rules. 

• Friday, 13 September 2024, 11:00 – 19:00 CEST
• Saturday, 14 September 2024, 08:00 – 19:30 CEST
• Sunday, 15 September 2024, 08:00 – 19:30 CEST
• Monday, 16 September 2024, 08:00 – 19:30 CEST
• Tuesday, 17 September 2024, 08:00 – 13:00 CEST

Press and Media Centre - CC3

The ESMO Press and Media Centre is located in hall CC3 at Fira Barcelona Gran Via (ESMO Congress 2024 venue).

At level 0, accredited Press Representatives can join the Press Working Room, while the Press Conference Room is located at level 1.

Both Press Representatives and Third Party Media can access the Filming Area, located at level 0.

Filming/Private rooms are located at level 1.

Please check the dedicated floorplan.

Contact 

Press Office: press@esmo.org  
Media Activities organised by Third Parties: media@esmo.org
Filming Activities: filming@esmo.org